Acorda Therapeutics Inc. (ACOR: Quote) announced Monday morning that data from a Phase 2 study of AMPYRA Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.
Acorda Therapeutics gapped up and rose sharply during the first 45 minutes of trade Monday, before settling into a range. The stock closed up by 3.98 at $35.50 on strong volume and broke out to a new high for the year.
Click here to receive FREE breaking news email alerts for Acorda Therapeutics Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com